VIR-576

Last updated
VIR-576
VIR-576 3D.gif
VIR-576 3D
Clinical data
Pregnancy
category
  • Unknown
ATC code
Legal status
Legal status
  • Under clinical trials
Identifiers
PubChem CID
ChemSpider
NIAID ChemDB
CompTox Dashboard (EPA)
Chemical and physical data
Formula C224H322N42O51S2
Molar mass 4483.40 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C)CCC(=O)O)CC(C)C)Cc6ccccc6)C(C)C)Cc7ccccc7)CCCCN)Cc8ccccc8)CC(C)C)Cc9ccccc9)CCC(=O)O)[C@@H](C)CC)CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
  • InChI=1S/C224H322N42O51S2/c1-23-131(17)183(255-187(279)135(21)230-192(284)146(89-93-177(271)272)234-189(281)145(227)107-125(5)6)220(312)263-103-59-85-171(263)212(304)251-165-123-318-319-124-166(207(299)250-164(122-268)205(297)258-186(134(20)26-4)223(315)266-106-62-88-174(266)219(311)262-102-58-84-170(262)209(301)237-149(92-96-180(277)278)195(287)244-158(114-140-69-41-30-42-70-140)200(292)240-154(110-128(11)12)198(290)242-156(112-138-65-37-28-38-66-138)191(283)229-120-176(270)233-151(80-52-54-98-226)217(309)260-100-56-82-168(260)211(303)246-161(117-143-75-47-33-48-76-143)203(295)254-182(130(15)16)215(307)248-162(224(316)317)118-144-77-49-34-50-78-144)252-213(305)172-86-60-104-264(172)221(313)184(132(18)24-2)256-188(280)136(22)231-193(285)147(90-94-178(273)274)235-196(288)152(108-126(7)8)238-201(293)159(115-141-71-43-31-44-72-141)247-214(306)181(129(13)14)253-202(294)160(116-142-73-45-32-46-74-142)245-210(302)167-81-55-99-259(167)216(308)150(79-51-53-97-225)232-175(269)119-228-190(282)155(111-137-63-35-27-36-64-137)241-197(289)153(109-127(9)10)239-199(291)157(113-139-67-39-29-40-68-139)243-194(286)148(91-95-179(275)276)236-208(300)169-83-57-101-261(169)218(310)173-87-61-105-265(173)222(314)185(133(19)25-3)257-204(296)163(121-267)249-206(165)298/h27-50,63-78,125-136,145-174,181-186,267-268H,23-26,51-62,79-124,225-227H2,1-22H3,(H,228,282)(H,229,283)(H,230,284)(H,231,285)(H,232,269)(H,233,270)(H,234,281)(H,235,288)(H,236,300)(H,237,301)(H,238,293)(H,239,291)(H,240,292)(H,241,289)(H,242,290)(H,243,286)(H,244,287)(H,245,302)(H,246,303)(H,247,306)(H,248,307)(H,249,298)(H,250,299)(H,251,304)(H,252,305)(H,253,294)(H,254,295)(H,255,279)(H,256,280)(H,257,296)(H,258,297)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,316,317)/t131-,132-,133-,134-,135-,136-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,181-,182-,183-,184-,185-,186-/m0/s1
  • Key:QMLQPHUSDUODMB-MFQMBSFASA-N

VIR-576 is an experimental drug that is under clinical trials for the treatment of HIV-1 infections. VIR-576 is synthetic peptide that binds to HIV-1's hydrophobic fusion peptide gp41, preventing the virus from inserting itself into a host cell's membrane to initiate an infection. [1] This drug is a synthesized variant of a highly specific natural entry inhibitor designated as VIRIP (virus-inhibitory peptide). [2]

Contents

The design of VIR-576 was based on VIRIP which in turn was discovered in 2007 by Frank Kirchhoff and coworkers. [3] This product is being developed by VIRO Pharmaceuticals GmbH & Co. KG. [4]

Origins and development

Estructura virip.png
Estructura vir576.png
Comparison between VIRIP (left) and VIR-576 (right) primary structures

In 2007, [5] a new natural peptide was discovered in the human organism and was called VIRIP. It is generated from alpha-1-antitrypsin, a protease inhibitor that belongs to the serine family, by matrix metalloproteinases. It was shown that it could interact with the HIV-1 and stop the virus multiplication. In spite of interacting in a highly intensity with gp-41, [2] the VIRIP did not prevent the multiplication of the virus. So, it was decided to increase the efficacy of this molecule creating other ones that could be more powerful. Among these 600 created molecules, [6] there was the VIR-576 which was synthesized using the solid-phase peptide synthesis method. Moreover, another molecule was used to protect the amino groups, the fluorenylmethyloxycarbonyl chloride. The next step was the purification before lyophilizing it with mannitol. Other peptides were made such as the VIR-353 or the VIR-449.[ citation needed ]

Structure

VIRIP secondary structure.png
VIR-576 secondary structure.png
Appearance of the secondary structures of VIRIP (left) and VIR-576 (right)

The VIR-576 is a peptide. [7] Consequently, it is a molecule formed by a sequence of amino-acids united by peptide bonds. If we compare both primary structures, it can be seen that the VIR-576 has 2 subunits. Each subunit, monomer is a variant form, a mutant of the VIRIP, [1] differing from four amino acids.

Thus, among the new ones introduced, it is important to emphasize the importance of the cysteine (C) introduced replacing the methionine (M), both being sulfated amino acids, in the stabilization of its structure.[ citation needed ]

VIR-576 can establish more hydrogen bonds because it has 41 H-bond donors and 56 H-bond acceptors [8] in comparison with the 23 H-bond donors and 30 H-bond acceptors [9] of the VIRIP.Therefore, it's able to form more interactions and react with the gp-41 in a higher intensity than the VIRIP.[ citation needed ]

Another important interaction that we must underline is the disulfide bond established between both cysteines of the two monomers of the VIR-576 which allows the peptide to have more structural stability in the space in comparison with the VIRIP. Moreover, the ring form that appears in the secondary structure is due to this interaction between both sulfate atoms. Thanks to this disulfide bond, a cystine is formed. This fact allows the union of the subunits during the reaction with the gp41 and also allows them to act simultaneously. Thanks to all this activity and to the dimerization respect to the VIRIP, the VIR-576 is more effective. [10]

Pharmacology

Mechanism of action

This image shows the different receptors and subunits involved in the mechanism of anchorage and fusion of HIV-1 with its target cell HIV attachment.gif
This image shows the different receptors and subunits involved in the mechanism of anchorage and fusion of HIV-1 with its target cell

VIR-576 belongs to a kind of drugs categorized as antiretroviral, specifically it is an anchoring inhibitor that blocks HIV-1 entry into the host cell. It binds to a concrete hydrophobic fusion peptide called gp41, which is a transmembrane glycoprotein located in the retrovirus HIV-1 envelope. [2] Target cell interacts with the gp41 peptide in order to form a pre-hairpin structure which joins HIV-1 and host cell membranes.[ citation needed ]

Gp41 is exposed with the assistance of another glycoprotein (gp120) also located in the envelope of the retrovirus. [11] The structural reason is based on the fact that two gp41 combine with other gp120 composing a trimer. [12] Firstly, it interacts with the receptor CD4 of a T4 human cell (also called Th or helper lymphocyte). The fusion causes an increase of concentration of HIV-1 on the target cell’s surface, and that promotes a switch which increases the affinity of gp120 for chemokine receptors that are disposed onto the target cell surface. This interaction produces a conformational change in the glycoprotein gp120 that exposes gp41. This process would be active because VIR-576 does not interferes in this part of it, but when gp41 is exposed, the developed drug VIR-576 would commence its mechanism of action and the inhibition of the fusion would start to take place.[ citation needed ]

VIR-576 binding to gp41 inhibits the anchoring of the virus and the membrane fusion, and that means that the genetic controlling material of the retrovirus HIV-1 can not be introduced in the T4 lymphocyte. As a result, infection would not be initiated.[ citation needed ]

Mechanism of action of Maraviroc and T-20. Comparison with VIR-576 HIV-1MARAV.png
Mechanism of action of Maraviroc and T-20. Comparison with VIR-576

Differences from other antiretroviral drugs

VIR-576 mechanism of action differs from other drugs. Enfuvirtide (also known as T-20), for example, is a fusion inhibitor which binds to a region of the glycoprotein gp41 called HR1 in order to prevent membrane fusion. [13] While enfurtivide inhibits the formation of the hairpin which is able to trigger the membrane fusion, VIR-576 directly blocks the insertion inhibiting the anchorage which is the previous stage of the hairpin formation (because to develop the hairpin it is necessary the fusion and VIR-576 impedes it. [2]

Dosage forms

VIR-576 is actually under clinical trials (together with Sifurtivide). In 2010, in order to examine the efficacy of the peptide, a short-term monotherapy [2] in HIV-infected patients was executed by a group of researchers. The results were proof of concept that fusion peptide inhibitors suppress viral replication in human patients, and offer prospects for the development of a new class of drugs that prevent virus particles from anchoring to and infecting host cells. The dosage form described below, belongs to the mentioned study.[ citation needed ]

Once the VIR-576 was chemically synthesized, it followed a purifying method that turned it into a highly pure drug substance, which was dehydrated in 500ml vials. Immediately before its use, the antiretroviral drug was dissolved in a second vial with bicarbonate-buddered saline, so it could be used in infusions.[ citation needed ]

The doses of VIR-576 were different between the groups of the study, but the highest one (5,0 grams per day) was the one which reduced more the viral load in the plasma.[ citation needed ]

Advantages

Compared with other antiretroviral drugs such as Enfuvirtide and Maraviroc, VIR-576’s mechanism has allowed it to being effective against resistant strains. [14] The reason why is so efficient is that gp41 protein can not mute, so, as a result VIR-576 will always be active as a HIV-1 fusion inhibitor.[ citation needed ]

Even since its discovery, VIRIP was more efficient to prevent HIV’s infection of T4 lymphocyte, independently of the presence of CCR5 receptors or CXCR4, and it was also effective against a large subtypes of HIV-1. [3]

The patients under treatment were carefully monitored, and most of them didn’t show secondary effects. Generally, the effects were temporal and tolerable like constipation, headaches, and fever, but a couple of patients showed allergic reactions and hyperbilirubinemia. The side effects were less severe in the high- dose treatment group and thus were not related to the dosage of VIR- 576. In conclusion, VIR-576 was well tolerated and did not cause major adverse effects.[ citation needed ]

See also

Related Research Articles

<span class="mw-page-title-main">HIV</span> Human retrovirus, cause of AIDS

The human immunodeficiency viruses (HIV) are two species of Lentivirus that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, the average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype.

<span class="mw-page-title-main">Glycoprotein</span> Protein with oligosaccharide modifications

Glycoproteins are proteins which contain oligosaccharide (sugar) chains covalently attached to amino acid side-chains. The carbohydrate is attached to the protein in a cotranslational or posttranslational modification. This process is known as glycosylation. Secreted extracellular proteins are often glycosylated.

<span class="mw-page-title-main">Enfuvirtide</span> Chemical compound

Enfuvirtide (INN), sold under the brand name Fuzeon, is an HIV fusion inhibitor, the first of a class of antiretroviral drugs used in combination therapy for the treatment of AIDS/HIV.

A coiled coil is a structural motif in proteins in which 2–7 alpha-helices are coiled together like the strands of a rope. They have been found in roughly 5-10% of proteins and have a variety of functions. They are one of the most widespread motifs found in protein-protein interactions. To aid protein study, several tools have been developed to predict coiled-coils in protein structures. Many coiled coil-type proteins are involved in important biological functions, such as the regulation of gene expression — e.g., transcription factors. Notable examples are the oncoproteins c-Fos and c-Jun, as well as the muscle protein tropomyosin.

This is a list of AIDS-related topics, many of which were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.

<span class="mw-page-title-main">Viral protein</span>

The term viral protein refers to both the products of the genome of a virus and any host proteins incorporated into the viral particle. Viral proteins are grouped according to their functions, and groups of viral proteins include structural proteins, nonstructural proteins, regulatory proteins, and accessory proteins. Viruses are non-living and do not have the means to reproduce on their own, instead depending on their host cell's machinery to do this. Thus, viruses do not code for most of the proteins required for their replication and the translation of their mRNA into viral proteins, but use proteins encoded by the host cell for this purpose.

<span class="mw-page-title-main">CD4</span> Marker on immune cells

In molecular biology, CD4 is a glycoprotein that serves as a co-receptor for the T-cell receptor (TCR). CD4 is found on the surface of immune cells such as helper T cells, monocytes, macrophages, and dendritic cells. It was discovered in the late 1970s and was originally known as leu-3 and T4 before being named CD4 in 1984. In humans, the CD4 protein is encoded by the CD4 gene.

The genome and proteins of HIV (human immunodeficiency virus) have been the subject of extensive research since the discovery of the virus in 1983. "In the search for the causative agent, it was initially believed that the virus was a form of the Human T-cell leukemia virus (HTLV), which was known at the time to affect the human immune system and cause certain leukemias. However, researchers at the Pasteur Institute in Paris isolated a previously unknown and genetically distinct retrovirus in patients with AIDS which was later named HIV." Each virion comprises a viral envelope and associated matrix enclosing a capsid, which itself encloses two copies of the single-stranded RNA genome and several enzymes. The discovery of the virus itself occurred two years following the report of the first major cases of AIDS-associated illnesses.

<span class="mw-page-title-main">Envelope glycoprotein GP120</span> Glycoprotein exposed on the surface of the HIV virus

Envelope glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope. It was discovered by Professors Tun-Hou Lee and Myron "Max" Essex of the Harvard School of Public Health in 1984. The 120 in its name comes from its molecular weight of 120 kDa. Gp120 is essential for virus entry into cells as it plays a vital role in attachment to specific cell surface receptors. These receptors are DC-SIGN, Heparan Sulfate Proteoglycan and a specific interaction with the CD4 receptor, particularly on helper T-cells. Binding to CD4 induces the start of a cascade of conformational changes in gp120 and gp41 that lead to the fusion of the viral membrane with the host cell membrane. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

<span class="mw-page-title-main">Gp41</span> Subunit of the envelope protein complex of retroviruses

Gp41 also known as glycoprotein 41 is a subunit of the envelope protein complex of retroviruses, including human immunodeficiency virus (HIV). Gp41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. As a result of its importance in host cell infection, it has also received much attention as a potential target for HIV vaccines.

Cyanovirin-N (CV-N) is a protein produced by the cyanobacterium Nostoc ellipsosporum that displays virucidal activity against several viruses, including human immunodeficiency virus (HIV). A cyanobacterial protein called cyanovirin-N (CV-N) has strong anti-human immunodeficiency virus (HIV) neutralizing properties. The virucidal activity of CV-N is mediated through specific high-affinity interactions with the viral surface envelope glycoproteins gp120 and gp41, as well as to high-mannose oligosaccharides found on the HIV envelope. In addition, CV-N is active against rhinoviruses, human parainfluenza virus, respiratory syncytial virus, and enteric viruses. The virucidal activity of CV-N against influenza virus is directed towards viral haemagglutinin.

Entry inhibitors, also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV and hepatitis D.

Group-specific antigen, or gag, is the polyprotein that contains the core structural proteins of an Ortervirus. It was named as such because scientists used to believe it was antigenic. Now it is known that it makes up the inner shell, not the envelope exposed outside. It makes up all the structural units of viral conformation and provides supportive framework for mature virion.

Env is a viral gene that encodes the protein forming the viral envelope. The expression of the env gene enables retroviruses to target and attach to specific cell types, and to infiltrate the target cell membrane.

<span class="mw-page-title-main">Vicriviroc</span> Chemical compound

Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue in patients previously untreated for HIV.

CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region, similarly known as immunoglobulin. It belongs to the antibody (Ig) gene family. CD4 is a surface receptor for human immunodeficiency virus (HIV). The CD4 immunoadhesin molecular fusion allow the protein to possess key functions from each independent subunit. The CD4 specific properties include the gp120-binding and HIV-blocking capabilities. Properties specific to immunoglobulin are the long plasma half-life and Fc receptor binding. The properties of the protein means that it has potential to be used in AIDS therapy as of 2017. Specifically, CD4 immunoadhesin plays a role in antibody-dependent cell-mediated cytotoxicity (ADCC) towards HIV-infected cells. While natural anti-gp120 antibodies exhibit a response towards uninfected CD4-expressing cells that have a soluble gp120 bound to the CD4 on the cell surface, CD4 immunoadhesin, however, will not exhibit a response. One of the most relevant of these possibilities is its ability to cross the placenta.

<span class="mw-page-title-main">HLA-DMB</span> Protein-coding gene in the species Homo sapiens

HLA class II histocompatibility antigen, DM beta chain is a protein that in humans is encoded by the HLA-DMB gene.

<span class="mw-page-title-main">HLA-DMA</span> Protein-coding gene in the species Homo sapiens

HLA class II histocompatibility antigen, DM alpha chain is a protein that in humans is encoded by the HLA-DMA gene.

2F5 is a broadly neutralizing human monoclonal antibody (mAb) that has been shown to bind to and neutralize HIV-1 in vitro, making it a potential candidate for use in vaccine synthesis. 2F5 recognizes an epitope in the membrane-proximal external region (MPER) of HIV-1 gp41. 2F5 then binds to this epitope and its constant region interacts with the viral lipid membrane, which neutralizes the virus.

CCR5 receptor antagonists are a class of small molecules that antagonize the CCR5 receptor. The C-C motif chemokine receptor CCR5 is involved in the process by which HIV, the virus that causes AIDS, enters cells. Hence antagonists of this receptor are entry inhibitors and have potential therapeutic applications in the treatment of HIV infections.

References

  1. 1 2 Liz Highleyman (2011). "Novel Entry Inhibitor VIR-576 Shows Promise in Early Study". hivandhepatitis.com.
  2. 1 2 3 4 5 Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Tillmann HC, Barlos K, Busmann A, Canales-Mayordomo A, Giménez-Gallego G, Hirsch J, Jiménez-Barbero J, Meyer-Olson D, Münch J, Pérez-Castells J, Ständker L, Kirchhoff F, Schmidt RE (December 2010). "Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide". Sci Transl Med. 2 (63): 63re3. doi:10.1126/scitranslmed.3001697. hdl: 10261/52876 . PMID   21178138. S2CID   24783051.
  3. 1 2 "El descubrimiento de un inhibidor del VIH en sangre humana apunta a un nuevo tipo de inhibidor de la fusión" [The discovery of an HIV inhibitor in human blood points to a new kind of fusion inhibitor] (in Spanish).
  4. ↑ Kelland K (2010). "VIR-576: Experimental HIV medicine can halt one of the earliest stages of HIV". Reuters.
  5. ↑ Poveda E (2007). "Discovery of VIRIP--a natural HIV entry inhibitor" (PDF). AIDS Rev. 9 (2): 126. PMID   17694679.
  6. ↑ Lic. Aleida Figueroa Silverio (2010). "Diseñan nuevo fármaco capaz de frenar la entrada del VIH en las células" [They design new drug able to slow the entry of HIV into cells] (in Spanish).
  7. ↑ Jefferys R (2011). "Anchors Away: New HIV Entry Inhibitor Study Creates a Splash". Treatment Action Group (TAG).
  8. ↑ "AIDS#: 472841". NIAID database. U.S. National Institute of Allergy and Infectious Diseases.
  9. ↑ "[A20]VIRIP - Compound Summary". PubChem.
  10. ↑ González-Ortega E, Ballana E, Badia R, Clotet B, Esté JA (December 2011). "Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1". Antiviral Res. 92 (3): 479–83. doi:10.1016/j.antiviral.2011.10.010. PMID   22027647.
  11. ↑ O'Brien WA (July 31, 2001). "HIV entry—from molecular insights to specific inhibitors". Medscape HIV/AIDS Conference Coverage. Medscape.
  12. ↑ Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH (November 2008). "Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs". PLOS Pathog. 4 (11): e1000203. doi: 10.1371/journal.ppat.1000203 . PMC   2577619 . PMID   19008954.
  13. ↑ Patel IH, Zhang X, Nieforth K, Salgo M, Buss N (2005). "Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide". Clin Pharmacokinet. 44 (2): 175–86. doi:10.2165/00003088-200544020-00003. PMID   15656696. S2CID   2516685.
  14. ↑ Gonzalez E, Ballana E, Clotet B, Esté JA (August 2011). "Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP)". AIDS. 25 (13): 1557–83. doi: 10.1097/QAD.0b013e328348a733 . PMID   21572303. S2CID   44666566.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.